Skip to main content
SpringerLink
Log in

Humira [Abbott, Eisai] will overtake Remicade [Centocor, Schering-Plough, Mitsubishi Tanabe] as the Crohn's disease market leader by 2012

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources.Humira Will Overtake Remicade as the Crohn's Disease Market Leader By 2012. Media Release: 1 Dec 2008. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Humira [Abbott, Eisai] will overtake Remicade [Centocor, Schering-Plough, Mitsubishi Tanabe] as the Crohn's disease market leader by 2012. Pharmacoecon. Outcomes News 569, 11 (2009). https://doi.org/10.2165/00151234-200905690-00029

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905690-00029

Keywords

Search

Navigation